3 Key Takeaways
Plain English Summary- 01Core Finding
Here, we aim to provide a practical framework for revaccination in patients with autoimmune diseases.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
What This Means for You
We propose a pragmatic revaccination approach after BCMA-targeting therapies in adult patients with autoimmune diseases, utilising minimal serologic monitoring. Future studies of these novel drugs will refine our understanding of the optimal timing and need for revaccinations in this population.
The Discovery
B-cell-directed immune-reset therapies are emerging as transformative approaches in autoimmune diseases, but their impact on long-term humoral immunity remains uncertain. These strategies encompass a broad range of B-cell targets and therapeutic modalities, the most clinically established targets include CD19, CD20, and B-cell maturation antigen (BCMA), with T-cell-redirecting approaches, particularly chimeric antigen receptor T-cell therapies and bispecific T-cell engagers, among the most validated modalities. Here, we aim to provide a practical framework for revaccination in patients with autoimmune diseases. We examine existing clinical evidence on the effects of BCMA-targeting therapies with respect to antivaccine titres to provide a revaccination framework in autoimmunity. Current clinical evidence suggests that BCMA-targeting therapies reduce vaccine-specific antibody titres along with total immunoglobulin levels. Insights from oncology studies provide a framework for understanding antivaccine responses in the context of profound BCMA-directed cell depletion, with the caveat that important differences exist between patients with autoimmunity and those with malignancies, including the magnitude and duration of immunosuppressive treatment.
How It Works, Simply
This immunology research focuses on antibodies · T cells · Immune response. Researchers evaluated it using an observational cohort study at the real-world cohort stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Here, we aim to provide a practical framework for revaccination in patients with autoimmune diseases.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
Biological Mechanism & Study Design
Study Design & Cohort
Observational cohort study
Observational cohort study · Real-World Cohort
Biological Pathway & Modality
Antibodies · T cells · Immune response
Intervention: Practical recommendations for revaccination following BCMA-targeted therapies in
Experimental Findings & Endpoints
B-cell-directed immune-reset therapies are emerging as transformative approaches in autoimmune diseases, but their impact on long-term humoral immunity remains uncertain.
These strategies encompass a broad range of B-cell targets and therapeutic modalities, the most clinically established targets include CD19, CD20, and B-cell maturation antigen (BCMA), with T-cell-redirecting approaches, particularly chimeric antigen receptor T-cell therapies and bispecific T-cell engagers, among the most validated modalities. Here, we aim to provide a practical framework for revaccination in patients with autoimmune diseases.
We examine existing clinical evidence on the effects of BCMA-targeting therapies with respect to antivaccine titres to provide a revaccination framework in autoimmunity. Current clinical evidence suggests that BCMA-targeting therapies reduce vaccine-specific antibody titres along with total immunoglobulin levels.
Insights from oncology studies provide a framework for understanding antivaccine responses in the context of profound BCMA-directed cell depletion, with the caveat that important differences exist between patients with autoimmunity and those with malignancies, including the magnitude and duration of immunosuppressive treatment.
Clinical Translation & Practice Context
We propose a pragmatic revaccination approach after BCMA-targeting therapies in adult patients with autoimmune diseases, utilising minimal serologic monitoring.
Future studies of these novel drugs will refine our understanding of the optimal timing and need for revaccinations in this population.
The Bottom Line · Clinical Pearl
“We propose a pragmatic revaccination approach after BCMA-targeting therapies in adult patients with autoimmune diseases, utilising minimal serologic monitoring.”
Published in Annals of the Rheumatic Diseases · Current Stage: Real-World Cohort
